|Drug Name||GPCR-targeted Project 007|
A bispecific antibody that simultaneously targets two cancer stem cell receptors (LGR5 and LGR4) is in early preclinical development for the treatment of solid tumors.
|Target||Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4); Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5)|
|Drug Modality||Bispecific antibody|
|Mechanism of Action||G protein-coupled receptor antagonists|
We look forward to hearing from you.